BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ShangPharma Purchases Shanghai In-vivo Drug Research Facility From Charles River Laboratories (Massachusetts)


10/24/2011 11:53:32 AM

SHANGHAI, Oct. 24, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has, through its main Chinese subsidiary, Shanghai ChemPartner Co. Ltd. ("ChemPartner"), acquired the assets in Charles River Laboratories International, Inc.'s ("Charles River") Shanghai research facility.

As part of the transaction, ShangPharma will take over Charles River's lease for the facility, which will provide the Company with an additional 2,972 square meters (31,990 square feet) of in-vivo research facilities originally designed for GLP Tox studies, and 1,290 square meters (13,885 square feet) of lab and office space.

"The acquisition of one of the best designed and constructed state-of-the-art research facilities and laboratories in China is a major step forward for ShangPharma's in-vivo pharmacology services, which we expect to be a significant revenue growth driver going forward, along with biologics; research manufacturing; and integrated discovery and development services," Michael Xin Hui, founder and Chief Executive Officer of ShangPharma, commented. "The added world-class research capacity should enable ShangPharma to become a top global player in the area of comprehensive in-vivo pharmacology services with specialized capabilities."

Kevin Chen, ShangPharma's President and Chief Operating Officer, commented, "This transaction nearly triples ShangPharma's overall research model production and research capacity, positioning us to further leverage China's advantages in the area of in-vivo studies. The location of this facility within ShangPharma's main research campus is a notable strategic advantage, helping us to achieve significant operating efficiencies through consolidation with our current facilities."

"This acquisition from Charles River should support accelerated growth in ShangPharma's biology, preclinical development and biologics services for the next several years," added William Dai, ShangPharma's Chief Financial Officer. "ShangPharma's strong cash position has enabled us to make this strategic investment, which we expect will provide excellent returns and maximize shareholder value."

Financial terms of the deal, which is subject to customary closing conditions, were not announced.

ABOUT SHANGPHARMA CORPORATION

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.

For further information, please contact:

ShangPharma
Ms. Lan Xie
VP of Finance and Investor Relations
Email: ir@shangpharma.com

Brunswick Group
Josh Gartner
Email: shangpharma@brunswickgroup.com
Phone: 86-10-5960-8600

SOURCE ShangPharma Corporation



Read at BioSpace.com
Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES